Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts

Toxicology Letters

Volumn 170, Issue 1, 2007, Pages 30-41

  Gao, Ai ^a   Liu, Bingci ^a   Shi, Xianglin ^b   Jia, Xiaowei ^a   Ye, Meng ^a   Jiao, Shi ^a   You, Baorong ^a   Huang, Chuanshu ^c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Chinese Academy of Sciences   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; B(a)P; Cell cycle; p70S6K; Signaling pathway

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; CELL CYCLE PROTEIN; CYCLIN D1; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; RETINOBLASTOMA PROTEIN; S6 KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPOSURE; HUMAN; HUMAN CELL; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZO(A)PYRENE; CARCINOGENS, ENVIRONMENTAL; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; HUMANS; LUNG; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 33947711258     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2007.02.008     Document Type: Article

References (63)

1. Aguirre D., Boya P., Bellet D., Faivre S., Troalen F., Benard J., et al. Bcl-2 and CCND1/CDK4 as molecular markers of the cellular effects of mTOR inhibitors in human ovarian carcinomas cells. Apoptosis 9 (2004) 797-805
2. Albanese C., Watanabe G., Johnson J., Eklund N., Vu D., Arnold A., et al. Transforming p21ras mutants and c-Ets 2 activate the Cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270 (1995) 23589-23597
3. Assoian R.K., and Schwartz M.A. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr. Opin. Genet. Dev. 11 (2001) 48-53
4. Bacus S.S., Altomare D.A., Lyass L., Chin D.M., Farrell M.P., Gurova K., et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21 (2002) 3532-3540
5. Banerjee R., Caruccio L., Zhang Y.J., McKercher S., and Santella R.M. Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology 32 (2000) 367-374
6. Barthelman M., Chen W., Gensler H.L., Huang C., Dong Z., and Bowden G.T. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res. 58 (1998) 711-716
7. Binkova B., and Sram R.J. The genotoxic effect of carcinogenic PAHs, their artificial and environmental mixtures (EOM) on human diploid lung fibroblasts. Mutat. Res. 547 (2004) 109-121
8. Brennan P., Babbage J.W., Burgering B.M.T., Groner B., Reif K., and Cantrell D.A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7 (1997) 679-689
9. Brennan P., Babbage J.W., Thomas G., and Cantrell D. p70S6K integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol. Cell. Biol. 19 (1999) 4729-4738
10. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4240-4245
11. Chen L., Devanesan P.D., Higginbotham S., Ariese F., Jankowiak R., Small G.J., et al. Expanded analysis of benzo(a)pyrene-DNA adducts formed in vitro and in mouse skin: their significance in tumor initiation. Chem. Res. Toxicol. 9 (1996) 897-903
12. Chen E.Y., Mazure N.M., Cooper J.A., and Giaccia A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 61: (2001) 2429-2433
13. Chen R., Ding W.V., and McCormick F. Wnt signaling to β-catenin involves two interactive components. Glycogen synthase kinase-3 inhibition and activation of protein kinase C. J. Biol. Chem. 275 (2000) 17894-17899
14. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3636-3641
15. Chu M., Guo J., and Chen C.Y. Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J. Biol. Chem. 280 (2005) 6369-6379
16. Clarke N., Arenzana N., Hai T., Minden A., and Prywes R. Epidermal growth factor induction of the c-jun promoter by a Rac pathway. Mol. Cell. Biol. 18 (1998) 1065-1073
17. Coffer P.J., Jin J., and Woodgett J.R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335 (1998) 1-13
18. Courjal F., Louason G., Speiser P., Katsoros D., Zeillinger R., and Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer 69 (1996) 247-253
19. Diehl J.A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 1 (2002) 226-231
20. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 (1998) 3499-3511
21. Drukteinis J.S., Medrano T., Ablordeppey E.A., Kitzman J.M., and Shiverick K.T. Benzo(a)pyrene, but not 2,3,7,8-TCDD, induces G2/M cell cycle arrest, p21CIP1 and p53 phosphorylation in human choriocarcinoma JEG-3 cells: a distinct signaling pathway. Placenta 26 Suppl. A (2005) S87-S95
22. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., and Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275 (1997) 661-665
23. Gao A., Liu B., Huang C., Shi X., Jia X., You B., et al. ERK and JNK/AP-1 Pathways Involved in Benzo(a)pyrene-induced cell cycle changes in human embryo lung fibroblasts. Chin. J. Ind. Hyg. Occup. Dis. 24 2 (2006) 72-76
24. Gille H., and Downward J. Multiple ras effector pathways contribute to G1 cell cycle progression. J. Biol. Chem. 274 (1999) 22033-22040
25. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., et al. Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27 kip1 expression. J. Biol. Chem. 275 (2000) 24500-24505
26. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25 (1961) 585-621
27. Hsu J.H., Shi Y., Krajewski S., Renner S., Fisher M., Reed J.C., et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 98 (2001) 2853-2855
28. Huang C., Li J., Ma W.Y., and Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem. 274 (1999) 29672-29676
29. Huang C., Ma W.Y., and Dong Z. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells. Oncogene 18 (1999) 2828-2835
30. Huang C., Ma W.Y., and Dong Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P_cells. Mol. Cell. Biol. 16 (1996) 6427-6435
31. Huang C., Ma W.Y., Young M.R., Colburn N., and Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 156-161
32. Huang C., Schmid P.C., Ma W.Y., Schmid H.H., and Dong Z. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J. Biol. Chem. 272 (1997) 4187-4194
33. Jadayel D.M., Lukas J., Nacheva E., Bartkova J., Stranks G., De Schouwer P.J., et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 11 (1997) 64-72
34. Karin M. Signal transduction from cell surface to nucleus in development and disease. FASEB J. 6 (1992) 2581-2590
35. Kovary K., and Bravo R. The fos and jun protein families are both required for cell cycle progression in fibroblasts. Mol. Cell. Biol. 11 (1991) 4466-4472
36. La Thangue N.B. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci. 19 (1994) 108-114
37. Lee H.Y., Oh S.H., Woo J.K., Kim W.Y., Van Pelt C.S., Price R.E., et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J. Natl. Cancer Inst. 97 (2005) 1695-1699
38. Li J., Tang M.S., Liu B., Shi X., and Huang C. A critical role of PI-3K/Akt/JNKs pathway in benzo(a)pyrene diol-epoxide (B(a)PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells. Oncogene 23 (2004) 3932-3944
39. Lukas J., Aagaard L., Strauss M., and Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 55 (1995) 4818-4823
40. Milde-Langosch K., Bamberger A.M., Methner C., Rieck G., and Loning T. Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int. J. Cancer 87 (2000) 468-472
41. Miller K.P., and Ramos K.S. Impact of cellular metabolism on the biological effects of benzo(a)pyrene and related hydrocarbons. Drug Metab. Rev. 33 (2001) 1-35
42. Moore S.M., Rintoul R.C., Walker T.R., Chilvers E.R., Haslett C., and Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70S6K-dependent pathway. Cancer Res. 58 (1998) 5239-5247
43. Muise-Helmericks R.C., Grimes H.L., Bellacosa A., Malstrom S.E., Tsichlis P.N., and Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273 (1998) 29864-29872
44. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., and Weigel R.J. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 274 (1999) 21528-21532
45. Nevins J.R. Transcriptional regulation: a closer look at E2F. Nature 358 (1992) 375-376
46. Olshan A.F., Weissler M.C., Pei H., Conway K., and Anderson S. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 14 (1997) 811-818
47. Page C., Huang M., Jin X., Cho K., Lilja J., Reynolds K.R., et al. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. J. Oncol. 17 (2000) 23-28
48. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., and Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21 (2002) 7435-7451
49. Roovers K., and Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioassays 22 (2000) 818-826
50. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
51. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev. 9 (1995) 1149-1163
52. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
53. Shi Y., Gera J., Hu L., Hsu J.H., Bookstein R., Li W., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62 (2002) 5027-5034
54. Solhaug A., Refsnes M., and Holme J.A. Role of cell signalling involved in induction of apoptosis by benzo(a)pyrene and cyclopenta(c,d)pyrene in Hepa1c1c7 cells. J. Cell. Biochem. 93 (2004) 1143-1154
55. Takuwa N., Fukui Y., and Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70S6K-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol. 19 (1999) 1346-1358
56. Tang O., Gonzales M., Inoue H., and Bowden G.T. Roles of Akt and glycogen synthetase kinase 3 in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res. 61 (2001) 4329-4332
57. Tannheimer S.L., Ethier S.P., Caldwell K.K., and Burchiel S.W. Benzo[a]pyrene- and TCDD-induced alterations in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line. Carcinogenesis 19 (1998) 1291-1297
58. Tsai K.S., Yang R.S., and Liu S.H. Benzo(a)pyrene regulates osteoblast proliferation through an estrogen receptor-related cyclooxygenase-2 pathway. Chem. Res. Toxicol. 17 (2004) 679-684
59. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
60. Yang D., Louden C., Reinhold D.S., Kohler S.K., Maher V.M., and McCormick J.J. Mammalian transformation of human fibroblast cell strain MSU-1.1 by (±)-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 2237-2241
61. Young M.R., Yang H.S., and Colburn N.H. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol. Med. 9 (2003) 36-41
62. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19 (2000) 2324-2330
63. Zhu H.J., and Gooderham N. Neoplastic transformation of human lung fibroblast MRC-5 SV2 cells induced by benzo[a]pyrene and confluence culture. Cancer Res. 62 (2002) 4605-4609